salicylates and betamethasone-17-21-dipropionate

Topics: Administration, Topical; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Glucocorticoids; Humans; Psoriasis; Salicylates; Salicylic Acid

Efficacy and tolerance of an alcoholic solution containing 0.64 mg betamethasone-dipropionate plus 20 mg salicylic acid (Diprosalic Solution) were compared with an alcoholic solution containing 0,64 mg betamethasone-dipropionate in a 3 week double blind study in 100 patients with psoriasis and other steroid-responsive dermatoses of dry nature, comprising scalp and other hairy and non-hairy areas of the body. This double blind study was followed by a 3 week open study in another 100 patients with similar diagnosis, using Diprosalic Solution only. Although the therapeutic results of the double blind study showed no significant differences between both treatment groups, distinct advantages of the drug containing salicylic acid could be clearly demonstrated, such as: 1. More rapid onset of action, 2. rapid clearing of scaling, pruritus and inflammation, 3. these advantages are in compliance with the fact that topically applied salicylic acid softens keratin, loosens cornified epithelium and desquamates the epidermis, making the underlying layers more accessible to the antiinflammatory steroid.

Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Clinical Trials as Topic; Dermatitis; Dermatitis, Seborrheic; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Eczema; Female; Glucocorticoids; Humans; Male; Middle Aged; Psoriasis; Salicylates; Salicylic Acid

Forty adult out-patients with erythematous squamous dermatoses of the scalp were treated in this 21-day double-blind study with an alcohol base lotion containing either 0.05% betamethasone-17,21-dipropionate, 2% salicylic acid, 0.05% betamethasone-17,21-dipropionate + 2% salicylic acid or their respective placebo. The four treatments were assigned randomly to the patients according to a 2 x 2 orthogonal factorial design. Changes in severity of redness, scaling, pruritus and size of lesions were evaluated. Since very few patients presented with excoriation and lichenification, these symptoms could not be ascertained. Results were assessed for significance by covariance analysis where initial status was used as regressor. A potentiation of the betamethasone-17,21-dipropionate activity by salicylic acid was observed for scaling. An additive effect was noted for redness and pruritus. According to the physician's global evaluation, patients treated with the combination drug showed a better evolution than those treated with placebo. The results suggest that addition of a keratolytic agent enhances the corticosteroid effect in the treatment of erythematous squamous dermatoses.

Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Betamethasone; Drug Combinations; Drug Evaluation; Drug Interactions; Drug Synergism; Female; Glucocorticoids; Humans; Male; Middle Aged; Psoriasis; Salicylates; Salicylic Acid; Scalp Dermatoses

A double-blind comparison was made between Diprosalic and Dermovate lotions in fifty-one patients with psoriasis of the scalp. Both preparations were highly effective. No significant difference in efficacy between the preparations could be demonstrated after 3 weeks treatment except for antipruritic effect, in this respect Diprosalic being superior to Dermovate. Only three patients (two in the Dermovate group, and one in the Diprosalic group) experienced minor adverse reactions. Plasma cortisol levels were determined in seventeen of the patients and no significant influence on the adrenal function could be shown on the part of either of the preparations.

Topics: Anti-Inflammatory Agents; Betamethasone; Clobetasol; Drug Evaluation; Female; Humans; Hydrocortisone; Male; Psoriasis; Salicylates; Scalp Dermatoses; Suspensions

In an open study, 38 patients suffering from psoriasis of the scalp with various degrees of severity and duration, were treated for 4 weeks with a lotion containing 0.05% betamethasone 17, 21-dipropionate and 2% salicylic acid in a paraben-free vehicle containing isopropyl alcohol. The results showed agreement between the overall evaluation of response by patients and the physician using a 60 mm visual scale analogue. Marked relief of symptoms appeared after 1 week of treatment while clinical improvement appeared after 2 weeks. Slight degree of induration was present in 1 patient after 4 weeks of treatment, while 8 patients showed slight degree of scaling. After 2 weeks, excoriation disappeared in all the patients treated. Overall tolerance and cosmetic acceptability of the preparation were good.

Topics: Adolescent; Adult; Aged; Betamethasone; Clinical Trials as Topic; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Psoriasis; Salicylates; Salicylic Acid; Scalp Dermatoses; Time Factors

Involvement of various cytokines in psoriasis pathomechanisms has previously been reported.. To better define the relationship between the disease severity and interleukin-6 and tumour necrosis factor alpha skin levels, these two cytokines were measured in suction blister fluids obtained from involved and uninvolved skin areas of psoriatic patients treated with UVB, beta-methasone dipropionate and salicylic acid ointment.. Determinations were performed by ELISA in fluids obtained from 6 patients with the Kiistala method, every 1-2 weeks for at least 1 month.. During the observation period, all the patients showed disease improvement (median PASI score declined from 13.4 to 3.9) and significant decreases in the cytokine levels in all samples.. These results are in agreement with a functional involvement of these two cytokines in the pathogenesis of the disease and their possible use as follow-up markers.

Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Betamethasone; Blister; Combined Modality Therapy; Exudates and Transudates; Female; Follow-Up Studies; Glucocorticoids; Humans; Interleukin-6; Middle Aged; Ointments; Psoriasis; Salicylates; Salicylic Acid; Skin; Tumor Necrosis Factor-alpha; Ultraviolet Therapy

Topics: Betamethasone; Drug Combinations; Gentamicins; Humans; Ointments; Salicylates; Skin Diseases

A multicentric open study was conducted to evaluate the efficacy and safety of betamethasone dipropionate and salicylic acid lotion in 86 patients with psoriasis or other steroid-responsive dermatoses of nonscalp body areas. Medication was applied to affected areas for 14 to 31 days. Patients were evaluated weekly. Within 14 to 21 days of therapy, there were favorable results in 68/86 (79%) patients. A complete clearing or marked improvement of signs and symptoms was achieved in 78/86 (91%) patients; improvement occurred in 7/86 (8%). Treatment failed in one (1%) patient. Three transient adverse reactions were reported.

Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Child; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Eczema; Female; Glucocorticoids; Humans; Male; Middle Aged; Psoriasis; Salicylates; Salicylic Acid; Skin Diseases